Cargando…
Mini-review of kidney disease following hematopoietic stem cell transplant
Advancements in hematopoietic cell transplantation (HCT) have broadened indications for its use and resulted in more long-term survivors. Stem cell transplantation is associated with several well-known toxicities, although renal complications are not well defined. Acute and chronic kidney disease re...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727568/ https://www.ncbi.nlm.nih.gov/pubmed/29578399 http://dx.doi.org/10.5414/CN109276 |
_version_ | 1783449279835144192 |
---|---|
author | Sedhom, Ramy Sedhom, Daniel Jaimes, Edgar |
author_facet | Sedhom, Ramy Sedhom, Daniel Jaimes, Edgar |
author_sort | Sedhom, Ramy |
collection | PubMed |
description | Advancements in hematopoietic cell transplantation (HCT) have broadened indications for its use and resulted in more long-term survivors. Stem cell transplantation is associated with several well-known toxicities, although renal complications are not well defined. Acute and chronic kidney disease remains a common complication following transplantation itself. Incidence and risk factors for the development of chronic kidney disease (CKD) is less well understood. Recent estimates suggest that nearly 15% of subjects undergoing HCT will develop CKD, a complication that can progress to end-stage renal disease (ESRD), disrupts overall quality of life, and reduces overall survival. Several commonly-reported risk factors include acute kidney injury, graft-versus-host disease, and long-term calcineurin inhibitor use. This review highlights the incidence, timeline, etiology, risk factors, and prognosis of kidney disease in the setting of hematopoietic stem cell transplantation. Investigation of the causes of CKD is needed, as are ways to prevent, mitigate, and treat kidney injury. Renal disease importantly reflects prognosis, with dialysis-requiring patients carrying greater than 80% mortality after 3 years. Although CKD following HCT is common, prospective studies are needed to confirm risk factors and better define the underlying mechanisms in order to promote therapies that prevent this complication.
|
format | Online Article Text |
id | pubmed-6727568 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dustri-Verlag Dr. Karl Feistle |
record_format | MEDLINE/PubMed |
spelling | pubmed-67275682019-10-30 Mini-review of kidney disease following hematopoietic stem cell transplant
Sedhom, Ramy Sedhom, Daniel Jaimes, Edgar Clin Nephrol Review Article Advancements in hematopoietic cell transplantation (HCT) have broadened indications for its use and resulted in more long-term survivors. Stem cell transplantation is associated with several well-known toxicities, although renal complications are not well defined. Acute and chronic kidney disease remains a common complication following transplantation itself. Incidence and risk factors for the development of chronic kidney disease (CKD) is less well understood. Recent estimates suggest that nearly 15% of subjects undergoing HCT will develop CKD, a complication that can progress to end-stage renal disease (ESRD), disrupts overall quality of life, and reduces overall survival. Several commonly-reported risk factors include acute kidney injury, graft-versus-host disease, and long-term calcineurin inhibitor use. This review highlights the incidence, timeline, etiology, risk factors, and prognosis of kidney disease in the setting of hematopoietic stem cell transplantation. Investigation of the causes of CKD is needed, as are ways to prevent, mitigate, and treat kidney injury. Renal disease importantly reflects prognosis, with dialysis-requiring patients carrying greater than 80% mortality after 3 years. Although CKD following HCT is common, prospective studies are needed to confirm risk factors and better define the underlying mechanisms in order to promote therapies that prevent this complication.
Dustri-Verlag Dr. Karl Feistle 2018-06 2018-03-26 /pmc/articles/PMC6727568/ /pubmed/29578399 http://dx.doi.org/10.5414/CN109276
Text en © Dustri-Verlag Dr. K. Feistle http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Sedhom, Ramy Sedhom, Daniel Jaimes, Edgar Mini-review of kidney disease following hematopoietic stem cell transplant |
title | Mini-review of kidney disease following hematopoietic stem cell transplant
|
title_full | Mini-review of kidney disease following hematopoietic stem cell transplant
|
title_fullStr | Mini-review of kidney disease following hematopoietic stem cell transplant
|
title_full_unstemmed | Mini-review of kidney disease following hematopoietic stem cell transplant
|
title_short | Mini-review of kidney disease following hematopoietic stem cell transplant
|
title_sort | mini-review of kidney disease following hematopoietic stem cell transplant
|
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727568/ https://www.ncbi.nlm.nih.gov/pubmed/29578399 http://dx.doi.org/10.5414/CN109276 |
work_keys_str_mv | AT sedhomramy minireviewofkidneydiseasefollowinghematopoieticstemcelltransplant AT sedhomdaniel minireviewofkidneydiseasefollowinghematopoieticstemcelltransplant AT jaimesedgar minireviewofkidneydiseasefollowinghematopoieticstemcelltransplant |